Case report

Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report

Guillermo A Escobar1, William A Robinson2, Trevor L Nydam1, Drew C Heiple2, Glen J Weiss2, Linda Buckley2, Rene Gonzalez2 and Martin D McCarter*1

Address: 1Department of Surgery, Division of GI, Tumor and Endocrine Surgery, University of Colorado Health Sciences Center. 4200 E. 9th Ave, Denver, CO, 80262, USA and 2Department of Medicine, Divisions of Medical Oncology and Endocrinology, University of Colorado Health Sciences Center. 4200 E. 9th Ave, Denver, CO, 80262, USA

Email: Guillermo A Escobar - guillermo.escobar@uchsc.edu; William A Robinson - william.robinson@uchsc.edu; Trevor L Nydam - trevor.nydam@uchsc.edu; Drew C Heiple - drew.heiple@uchsc.edu; Glen J Weiss - glen.weiss@uchsc.edu; Linda Buckley - linda.buckley@uchsc.edu; Rene Gonzalez - rene.gonzalez@uchsc.edu; Martin D McCarter* - martin.mccarter@uchsc.edu

* Corresponding author

Abstract

**Background:** Non-islet cell tumor induced hypoglycemia (NICTH) is a very rare phenomenon, but even more so in gastrointestinal stromal tumors. It tends to present in large or metastatic tumors, and can appear at any time in the progression of the disease. We present herein a case of NICTH in a GIST tumor and report an exon 9 mutation associated to it.

**Case presentation:** A thirty nine year-old man with a recurrent, metastatic gastrointestinal stromal tumor presented to the hospital with nausea, dizziness, loss of consciousness, and profound hypoglycemia (20 mg/dL). There was no evidence of factitious hypoglycemia. He was stabilized with a continuous glucose infusion and following selective vascular embolization, the patient underwent debulking of a multicentric 40 cm × 25 cm × 10 cm gastrointestinal stromal tumor. After resection, the patient became euglycemic and returned to his normal activities. Tumor analysis confirmed excessive production of insulin-like growth factor II m-RNA and the precursor protein, "big" insulin-like growth factor II. Mutational analysis also identified a rare, 6 bp tandem repeat insert (gctctat) at position 1530 in exon 9 of KIT.

**Conclusion:** Optimal management of gastrointestinal stromal tumor-induced hypoglycemia requires a multidisciplinary approach, and surgical debulking is the treatment of choice to obtain immediate symptomatic relief. Imatinib or combinations of glucocorticoids and growth hormone are alternative palliative strategies for symptomatic hypoglycemia. In addition, mutations in exon 9 of the tyrosine kinase receptor KIT occur in 11–20% of GIST and are often associated with poor patient outcomes. The association of this KIT mutation with non-islet cell tumor induced hypoglycemia has yet to be established.
Background
Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors most commonly found in the stomach or small intestine of adults. Their incidence ranges from 2.1 to 15 per million people, they are evenly distributed between genders, and 90% are CD-117 positive [1-3]. They usually grow asymptptomatically until they are discovered due to appearance of signs and symptoms related to mass effects, bleeding or bowel perforation [4-6]. Other very rare clinical manifestations of GIST include hyperpigmentation or mastocytosis (both found in inherited forms of GIST) [7,8] and hypoglycemia [9-12].

Expression of CD-117 is the diagnostic marker for GIST and is the transmembrane tyrosine kinase receptor also known as KIT or c-KIT [13]. The ligand for the receptor is stem-cell factor, which is essential for embryonic development and proliferation of a variety of cell types including melanocytes, gonadal cells, and interstitial cells of Cajal (GI tract pacemaker cells) [14]. The latter are thought to be the physiological precursors to gastrointestinal stromal tumors and their proliferation may be due to unregulated activation of KIT [15].

To follow is a unique case associating GIST-induced hypoglycemia due to overproduction of "big" insulin-like growth factor II with an exon 9 mutation.

Case presentation
A 39 year-old man with a multifocal abdominal recurrence of a small bowel gastrointestinal stromal tumor presented to the hospital following loss of consciousness preceded by weakness, dizziness and nausea. His serum glucose was 20 mg/dL (normal 80–110 mg/dL) and required a continuous infusion of high dose (10%) dextrose to maintain a serum glucose concentration above 70 mg/dL. Serologic workup demonstrated no evidence of factitious hypoglycemia and it discarded the diagnosis of islet cell-induced hypoglycemia. The insulin like growth factor (IGF) I and IGF binding protein 3 level were below the normal range, while insulin, pro-insulin, C-peptide and IGF II levels were all in the normal range (table 1).

An abdominal computed tomography demonstrated a large, multincetrical tumor with extensive collateral circulation (Fig 1a and 1b). Preoperative selective embolization of associated vessels was performed to reduce operative bleeding. The following day, extensive tumor debulking of both the dominant mass and 99% of the remaining multifocal 40 cm × 25 cm × 10 cm GIST was achieved (Fig 1c and 1d), obtaining an R1 resection. Immediately after completing the resection, the patient became euglycemic without requiring intravenous glucose. The patient was euglycemic, active and without radiographic evidence of progression 6 months after his surgery. Due to gastrointestinal intolerance to imatinib, he is currently on therapy with sunitinib with stable disease.

Pathologic analysis identified the presence of KIT (CD-117) in the tumor; confirming GIST histology. Extracted DNA was amplified by polymerase chain reaction for exons 9, 11, 13 and 17 of KIT. No mutations were found in exons 11, 13 or 17; however one allele at position 1530 in exon 9 contained a 6 bp tandem repeat insert (GCCTAT). This led to a duplication of amino acid residues alanine 502 and tyrosine 503 (Fig 2). The mutation was confirmed by a TOPO cloning system (Invitrogen, Carlsbad, California USA), which detected the presence of one normal allele and one with the 6 bp insert as described.

The patient's serum and tumor were sent to the University Medical Center in Utrecht (The Netherlands) for further analysis. The concentration of II E [68–88] ("big" IGF-II) in plasma was 51.9 ng/mL (normal: 6.5–17.5 ng/mL). The levels of IGF binding protein 6 (IGFBP-6) were reported to be within the normal range. In situ hybridization of the tumor samples demonstrated high expression of IGF II mRNA and elevated pro-IGF II (figure 3).

It has been found that specific KIT mutations in GIST may predict a patient's prognosis. Mutations on exon 11 are the most common (79%), while those on exon 9 are only found in about 11% of GIST. Most patients with exon 11 mutations respond to treatment with imatinib, while less than half of those with exon 9 mutations respond and are almost twice as likely to recur [16-18].

The particular mutation we found in our patient has been reported very infrequently, and is thought to induce a ligand-independent gain-of-function with homodimerization and constitutive autophosphorylation [19,20]. The significance of the association of this mutation and non-islet cell tumor hypoglycemia (NICTH) has yet to be established.

The incidence of NICTH is thought to be one fourth that of functional insulinomas (1 case of NICTH per million people-years) [21,22]. NICTH usually occurs with large or metastatic tumors that are usually of mesenchymal origin, but may also present in other types of cancer [23]. Searching via MEDLINE, PubMed, Gold Rush and article cross-referencing, we only found 4 other publications of NICTH in GIST; four of which had overexpression of "big" IGF II and in two there was overexpression of pro-IGF II [9-12].

High concentrations of pre-pro-IGF II genes that are not significantly higher affinity to the insulin receptor, and a
Table 1: Initial Evaluation for Sources of Hypoglycemia

|                      | Patient’s Serum | Normal Range       |
|----------------------|-----------------|--------------------|
| Insulin              | 2 μU/mL         | 0–20 μU/mL         |
| Pro Insulin          | 2.4 pmol/L      | 2.1–26.8 pmol/L    |
| C-peptide            | 0.6 ng/mL       | 1.1–4.6 ng/mL      |
| Cortisol             | 18 μg/dL        | 5–25 μg/dL         |
| Chlopropamide        | 0 μg/mL         | 0 μg/mL            |
| Tolazamide           | 0 μg/mL         | 0 μg/mL            |
| Tolbutamide          | 0 μg/mL         | 0 μg/mL            |
| Glynuride            | 0 μg/mL         | 0 μg/mL            |
| Glipizide            | 0 μg/mL         | 0 μg/mL            |
| Acetohexamide        | 0 μg/mL         | 0 μg/mL            |
| IGF Binding Protein-3| 1180 ng/mL      | 1237–2604 ng/mL    |
| IGF-I                | 40 ng/mL        | 90–360 ng/mL       |
| IGF-II               | 391 ng/mL       | 288–736 ng/mL      |

IGF = Insulin-like growth factor

Figure 1
1a and b- CT scan of the abdomen and pelvis with oral and intravenous contrast demonstrating a large, multicentric GIST with extensive collateral circulation extending from the upper abdomen to the pelvis. 1c and d- Intraoperative photos of the mass being delivered from the abdomen.
lower affinity to its binding protein [24,25]. The association of "big" IGF II and NICHT was first identified by Daughaday in a patient with a fibrosarcoma [26]. Non-islet cell tumor-induced hypoglycemia secondary to "big" IGF II is difficult to confirm because laboratory tests for it are not readily available. A landmark observation by Teale et al. was that IGF I and II levels in patients with hyperinsulinemic hypoglycemia were both usually low, while patients with NICHT had normal levels of IGF II [25]. Consequently, Hizuka et al. demonstrated that IGF I was always low in hypoglycemic patients with "big" IGF II, while those without elevated "big" IGF II had both low IGF I and II [27].

The management of most patients with NICHT requires prompt intravenous hydration and glucose infusions. Once stable, the ideal treatment is to remove the source of hypoglycemia. In NICHT, the hypoglycemia is not due to a dysfunctional insulin receptor nor abnormal K-ATP channels, therefore diazoxide is unlikely to be effective [28]. Attempts with imatinib as a first-line therapy may fail due to resistance to the drug, or take as long as 5 weeks before being able to interrupt the intravenous glucose infusions [10]. A recent report by Hamberg et al. [12] found in one patient with NICHT from GIST that elevated concentrations of imatinib seemed to worsen hypoglycemia, while another patient spontaneously resolved without any GIST-related therapy. Alternative nonoperative cytoreductive techniques such as selective embolization and radiofrequency ablation may have a role in alleviating hypoglycemia; however these have not been reported in the literature. Additionally, they may potentially result in greater circulating "big" IGF II during necrosis of the GIST and may explain Hamberg's findings in a patient treated with imatinib alone that had hypoglycemia proportional to the dose of imatinib. In other (non GIST) cases of NICHT, low dose steroids and growth hormone have allowed palliative weaning from intravenous glucose [25,29,30]. Surgical resection remains as the most rapid and cost-effective therapy to normalize glucose metabolism in most cases of NICHT.

**Conclusion**

Our experience and review of the literature suggest that a multidisciplinary approach is helpful in the management of NICHT in GIST and that prompt surgical debulking is the treatment of choice.

**Competing interests**

The author(s) declare that they have no competing interests.

**Authors' contributions**

GAE conceived and drafted the manuscript, obtained references, participated in its design and coordination and edited the figures and legends. WAR directed and obtained the GIST mutational analysis and participated in its design and editing. TLN participated in its drafting, references, editing and design. DCH contributed to the patient's care and contributed to the conception and drafting of the manuscript. GJW Performed the GIST mutational analysis and participated in its design and

---

**Figure 2**

Electropherogram of the mid portion of exon 9 of KIT from this patient’s GIST showing two alleles, one with a 6 bp tandem repeat insertion (GCCTAT) leading to a duplication of amino acids alanine and tyrosine at codons 502 and 503 (enclosed in the square).
coordination. LB contributed to the patient’s care and coordinated communication with the University Medical Center Utrecht, Utrecht, The Netherlands for obtaining molecular analysis of IGF. RG contributed to the patient’s care and participated in its editing, design and coordination. MDM contributed to the patient’s care, performed

Figure 3
3a- In situ hybridization: IGF-II mRNA sense probe (200×). 3b- In situ hybridization: IGF-II mRNA antisense probe (200×). 3c- Immunohistochemistry: Polyclonal rabbit anti E [68–88] domain of human pro-IGF-II (“big” IGF-II) (dilution 1:50) (200×). 3d- Immunohistochemistry: Polyclonal rabbit anti-human IGF-II (dilution 1:100) (200×).
surgical resection, obtained operative photos and participated in its design, editing and coordination. All authors read and approved the final manuscript.

Acknowledgements
We appreciate Dr. Jaap van Doorn and colleagues (University Medical Center Utrecht, Utrecht, The Netherlands) for analyzing and providing the images of the patient’s tissue and serum analysis for IGF II and “big” IGF II.

Written consent was obtained from the patient for the publication of this report.

References
1. Goetttsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC: Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study. Eur J Cancer 2005, 41(18):2868-2872.
2. Briand F, Peis-Kindt JM, Oden A, Dortok A, Gustavsson B, Sabinina K, Kindblom LG: Gastrointestinal stromal tumours: the incidence, prevalence, clinical course, and prognosis in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 2005, 103(4):821-829.
3. Tran T, Deroo HB: The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005, 100(1):162-168.
4. Connolly EM, Gaffney E, Reynolds JV: Non-islet-cell tumor induced hypoglycemia in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2002, 21(23):4342-4349.
5. Mattioli F, Puglisi M, Ceppa P, Peresi M, Borgonovo G, Ansaldo G, Varaldo E, Milone L, Assalino M, Torre GC: Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation. Am J Med Genet A 2005, 132(4):402-404.
6. Mehta RM, Sudheer VO, John AK, Nandakumar RR, Dhar PS, Sudhindran S, Bakristhavan V: Spontaneous rupture of giant gastric stromal tumor into gastric lumen. World J Surg Oncol 2005, 3(1):11.
7. Carballo M, Roig I, Aguilar F, Pol MA, Gamundi MJ, Hernan I, Martinez-Gimeno M: Novel c-KIT germinel mutation in a family with gastrointestinal stromal tumours and cutaneous hyperpigmentation. Am J Med Genet A 2005, 132(4):361-364.
8. Hartmann K, Wardellman E, Ma Y, Mielke-Bausch S, Preusner LM, Woolery C, Baldus SE, Heinicke T, Thiele J, Buetten R, Longley BJ: Novel germline mutation of KIT associated with familial gastrointestinal stromal tumours and mastocytosis. Gastroenterology 2005, 129(3):1042-1046.
9. Beckers MM, Snee PH, van Doorn J: Hypoglycaemia in a patient with a gastrointestinal stromal tumour. Clin Endocrinol (Oxf) 2005, 62(9):402-404.
10. Pink D, Schoeler D, Lindner T, Thuss-Patience JC, Kretzschmar A, Knipp H, Vanhoefer U, Reichardt P: Severe hypoglycaemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumours: a report of two cases. J Clin Oncol 2005, 23(27):6809-6811.
11. Rikhof B, Van Den Berg G, Van Der Graaf WT: Non-islet-cell tumour hypoglycaemia in a patient with a gastrointestinal stromal tumour. Acta Oncol 2005, 44(7):764-766.
12. Hanberg P, de Jong FA, Boonstra JG, van Doorn J, Verweij J, Sleijfer S: Non-islet cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol 2006, 24(18):e30-1.
13. Fletcher CD, Berman JJ, Corless CL, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW: Diagnosis of gastrointestinal stromal tumours: A consensus approach. Hum Pathol 2002, 33(5):459-465.
14. Miettinen M, Lasota J: KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistol Molec Pathol 2005, 13(3):255-220.
15. Roskoski Jr: Structure and regulation of Kit protein-tyrosine kinase—the stem cell factor receptor. Biochem Biophys Res Commun 2005, 338(3):1307-1315.
16. Heinrich MC, Corless CL, Demetri GD, Blankes PD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21(23):4342-4349.
17. Hostein I, Longy M, Gastaldello B, Ceseve G, Coindre JM: Detection of a new mutation in KIT exon 9 in a gastrointestinal stromal tumor. Int J Cancer 2005.
18. Debiec-Rychter M, Sciort R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom A T, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42(8):1093-1103.
19. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nasser A, Sobin LH, Miettinen M: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumours. A study of 200 cases. J Pathol 2000, 196(1):109-1095.
20. Lux ML, Rubin BP, Basse TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2001, 156(3):791-795.
21. Marks V, Teale JD: Tumours producing hypoglycaemia. Diabetes Metab Rev 1991, 7(2):79-91.
22. Service FJ, McMahon MM, O’Brien PC, Ballard DJ: Functioning insulinoma—incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991, 66(7):711-719.
23. Daughaday WH: Hypoglycemia in patients with non-islet cell tumors. Endocr Pathol Clin North Am 1989, 18(1):91-101.
24. Hostein K, van Doorn J, Gloudemans T, Maassen JA, Schuller AG, Pinedo HM: Hypoglycaemia associated with the production of insulin-like growth factor II and insulin-like growth factor binding protein 6 by a haemangiopericytoma. Clin Endocrinol (Oxf) 1999, 51(2):247-253.
25. Teale JD, Wark G: The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clin Endocrinol (Oxf) 2004, 60(4):457-460.
26. Daughaday WH, Kapadia M: Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycaemia in patients with non-islet-cell tumors. Proc Natl Acad Sci U S A 1989, 86(17):6778-6782.
27. Hizuka N, Fukuda I, Takano K, Okubo Y, Asakawa-Yasumoto K, Demura H: Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J 1998, 45(Suppl):S61-5.
28. Hussain K, Cosgrove KE, Shepherd RM, Chapman JC, Swift SM, Smith VW, Kassem SA, Glaser B, Lindley KJ, Aynsley-Green A, Dunne MJ: Uncontrolled insulin secretion from a childhood pancreatic beta cell adenoma is not due to the functional loss of ATP-sensitive potassium channels. Endocr Relat Cancer 2002, 9(4):221-226.
29. Bourcigaux N, Arnault-Ouay G, Christol R, Perin L, Charbonnel B, Bourgeois P, Dupont M: Hypoglycaemia during combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumour hypoglycemia. Clin Ther 2005, 27(2):246-251.
30. LeRoith D: Non-islet cell hypoglycemia. Ann Endocrinol (Paris) 2004, 65(1):99-103.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/7/13/prepub